ABSTRACT
Treatment with richlocaine alone and, especially, in combination with antihypoxant energostim decreased the total content of hydroxyproline in the ischemic skin flap on day 3 after excision. Combination therapy with richlocaine and energostim normalized the redox potential in the energy supply system, improved antioxidant protection, and promoted the recovery of a balance between various components in the antioxidant system. These changes were not accompanied enhanced production of malonic dialdehyde. Our results suggest that combination therapy with richlocaine and energostim maintains the adaptive reserves of detoxifying systems in keratinocytes and prevents endotoxemia. Richlocaine primarily stimulates glycolytic synthesis of ATP, activates nonmitochondrial antioxidant enzymes, and increases RNase activity in lysosomes.
Subject(s)
Antioxidants/pharmacology , Hypoxia , Ischemia , Keratinocytes/drug effects , Keratinocytes/pathology , Malondialdehyde/analogs & derivatives , Piperidines/pharmacology , Adenosine Triphosphate/chemistry , Animals , Antioxidants/chemistry , Electron Transport , Endotoxemia/metabolism , Glycolysis , Keratinocytes/metabolism , Lysosomes/metabolism , Male , Malondialdehyde/metabolism , Mitochondria/pathology , Oxidation-Reduction , Rats , Ribonucleases/metabolism , Skin/pathology , Time FactorsABSTRACT
The local anesthetic richlocaine decreased the area of necrosis in the skin flap under conditions of reduced blood flow by 29.5%. Improved survival of skin flap after richlocaine treatment alleviated endogenous intoxication, reduced secondary inflammatory reaction, improved liver function, and normalized the ratio between vasoconstricting and vasodilating prostaglandins. This effect was most pronounced after combination therapy with richlocaine and direct-action antihypoxant energostim.
Subject(s)
Antioxidants/pharmacology , Cytochromes c/pharmacology , Endotoxemia/drug therapy , Inosine/pharmacology , NAD/pharmacology , Piperidines/pharmacology , Skin/drug effects , Skin/pathology , Alanine Transaminase/metabolism , Animals , Aspartate Aminotransferases/metabolism , Cell Survival , Drug Combinations , Endotoxemia/metabolism , Erythrocytes/metabolism , Histamine/metabolism , Hydroxyproline/chemistry , Hypoxia , Inflammation , Keratinocytes/metabolism , Lactates/metabolism , Male , Necrosis , Rats , Regional Blood Flow , Serotonin/metabolism , Surgical Flaps/pathology , Time Factors , Vasodilator Agents/pharmacologyABSTRACT
The results of combined therapy of chronic moderate generalized periodontitis can be improved by adding richlocaine to protocols of drug therapy: the drug reduces the time of treatment, prolongs remission, decreases the number of relapses, and stabilizes pathological processes in periodontal tissues.
Subject(s)
Analgesics/therapeutic use , Anti-Bacterial Agents/therapeutic use , Periodontitis/drug therapy , Periodontitis/prevention & control , Piperidines/therapeutic use , Adult , Aged , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Male , Middle Aged , Periodontitis/diagnostic imaging , Periodontitis/pathology , Radiography , Secondary PreventionABSTRACT
We studied the effect of local anesthetic richlocaine on proliferation and intracellular calcium content in cultured osteoblasts from rat parietal bone. In a concentration of 1 mg/ml this drug produced a cytotoxic effect on osteoblasts. In concentrations of 0.01 and 0.001 mg/ml richlocaine in the absence and presence of subtoxic dose of sodium cyanide (0.2 mM) increased the number of osteoblasts by 15.4 and 36.6 or 13.8 and 38.6%, respectively. In a concentration of 1 mg/ml, richlocaine increased the content of cytosolic calcium in osteoblasts by 105%. These effects of richlocaine in low concentrations (0.01 and 0.001 mg/ml) can be related to stimulation of metabolic processes in osteoblasts.
